Teva Q3 2026: Branded Portfolio Up 33%, Guidance Raised
As seen on the 24/7 Wall St. homepage on November 3, 2026.
Teva's innovative brands AUSTEDO, AJOVY and UZEDY grew 33% in local currency, offsetting the lenalidomide-driven slide in U.S. generics revenue. Both lines came in ahead of expectations, and management raised full-year revenue guidance to $16.7 to $17.0 billion.
Continue ReadingShow less
Teva's branded portfolio grew 33% in local currency, beating expectations and shifting the growth engine away from generics.
AUSTEDO, AJOVY, and UZEDY together generated roughly $1.1 billion in the quarter, richening the product mix and widening gross margin.
U.S. generics revenue fell 39% as competition for lenalidomide intensified, capping the headline growth.
Sponsored
Management raised the full-year 2026 revenue outlook to $16.7 to $17.0 billion and lifted targets for all three key growth products.
FDA approval for WELTRUZA and a return to investment grade from all three major rating agencies keep the turnaround on solid footing.